vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
Piedmont Realty Trust, Inc. is the larger business by last-quarter revenue ($143.3M vs $94.9M, roughly 1.5× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs -31.4%, a 59.8% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 0.4%). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 0.0%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
DVAX vs PDM — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $143.3M |
| Net Profit | $26.9M | $-45.0M |
| Gross Margin | — | — |
| Operating Margin | 22.4% | — |
| Net Margin | 28.4% | -31.4% |
| Revenue YoY | 17.7% | 0.4% |
| Net Profit YoY | 53.0% | -27.9% |
| EPS (diluted) | $0.21 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.3M | ||
| Q4 25 | — | $142.9M | ||
| Q3 25 | $94.9M | $139.2M | ||
| Q2 25 | $95.4M | $140.3M | ||
| Q1 25 | $68.2M | $142.7M | ||
| Q4 24 | $72.0M | $143.2M | ||
| Q3 24 | $80.6M | $139.3M | ||
| Q2 24 | $73.8M | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | — | $-43.2M | ||
| Q3 25 | $26.9M | $-13.5M | ||
| Q2 25 | $18.7M | $-16.8M | ||
| Q1 25 | $-96.1M | $-10.1M | ||
| Q4 24 | $7.0M | $-30.0M | ||
| Q3 24 | $17.6M | $-11.5M | ||
| Q2 24 | $11.4M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.4% | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | -34.7% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 12.5% | — | ||
| Q2 24 | 7.0% | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | — | -30.3% | ||
| Q3 25 | 28.4% | -9.7% | ||
| Q2 25 | 19.6% | -12.0% | ||
| Q1 25 | -141.0% | -7.1% | ||
| Q4 24 | 9.8% | -20.9% | ||
| Q3 24 | 21.8% | -8.3% | ||
| Q2 24 | 15.4% | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | — | $-0.34 | ||
| Q3 25 | $0.21 | $-0.11 | ||
| Q2 25 | $0.14 | $-0.14 | ||
| Q1 25 | $-0.77 | $-0.08 | ||
| Q4 24 | $0.07 | $-0.25 | ||
| Q3 24 | $0.12 | $-0.09 | ||
| Q2 24 | $0.08 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $534.1M | $1.5B |
| Total Assets | $946.5M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.3M | ||
| Q4 25 | — | $731.0K | ||
| Q3 25 | $160.2M | $3.0M | ||
| Q2 25 | $99.1M | $3.3M | ||
| Q1 25 | $51.7M | $2.9M | ||
| Q4 24 | $95.9M | $109.6M | ||
| Q3 24 | $119.3M | $133.6M | ||
| Q2 24 | $112.5M | $138.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | $534.1M | $1.5B | ||
| Q2 25 | $494.2M | $1.5B | ||
| Q1 25 | $530.9M | $1.6B | ||
| Q4 24 | $596.8M | $1.6B | ||
| Q3 24 | $681.4M | $1.6B | ||
| Q2 24 | $642.8M | $1.7B |
| Q1 26 | — | $4.0B | ||
| Q4 25 | — | $4.0B | ||
| Q3 25 | $946.5M | $4.0B | ||
| Q2 25 | $918.4M | $4.0B | ||
| Q1 25 | $945.9M | $4.0B | ||
| Q4 24 | $986.3M | $4.1B | ||
| Q3 24 | $1.1B | $4.1B | ||
| Q2 24 | $1.0B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | — |
| Free Cash FlowOCF − Capex | $32.6M | — |
| FCF MarginFCF / Revenue | 34.4% | — |
| Capex IntensityCapex / Revenue | 1.3% | 110.3% |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $140.6M | ||
| Q3 25 | $33.8M | $35.8M | ||
| Q2 25 | $23.4M | $50.1M | ||
| Q1 25 | $-19.6M | $3.7M | ||
| Q4 24 | $53.0M | $198.1M | ||
| Q3 24 | $19.5M | $42.9M | ||
| Q2 24 | $10.7M | $66.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $32.6M | — | ||
| Q2 25 | $22.0M | — | ||
| Q1 25 | $-23.6M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $18.1M | — | ||
| Q2 24 | $9.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 34.4% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -34.6% | — | ||
| Q4 24 | 68.8% | — | ||
| Q3 24 | 22.5% | — | ||
| Q2 24 | 13.5% | — |
| Q1 26 | — | 110.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
PDM
Segment breakdown not available.
